Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives
Eurasian Journal of Medicine and Oncology · 07.08.2026 · 10 (5) · 026270318
DOI: 10.36922/ejmo026270318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 07.08.2026. Verfasst von Venkata Bharat Kumar Pinnelli und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The therapeutic landscape of chronic myeloid leukemia (CML) represents a paradigm of precision oncology, evolving across multiple generations of targeted breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 tyrosine kinase inhibitors. As survival approaches that of the general population, long-term care requires balancing drug efficacy with safety, sequencing optimization, and survivorship considerations.
Objectives
This review aims to evaluate modern CML management strategies, including drug mechanisms, resistance mutations, toxicity profiles, treatment sequencing, and criteria for treatment discontinuation.
Methods
Literature was retrieved up to June 2026 using databases indexing landmark phase I–III trials, European LeukemiaNet guidelines, and regulatory data. Evidence was synthesized thematically across adult chronic-phase CML management strategies to evaluate drug mechanisms, resistance mutations, organ-specific toxicities, and treatment discontinuation criteria.
Results
First-generation imatinib provides a well-characterized safety profile but is associated with slower response kinetics. Second-generation agents (e.g., dasatinib, nilotinib, bosutinib) achieve deeper molecular responses but present distinct, non-overlapping toxicities—including pleural, vascular, metabolic, and gastrointestinal complications—and remain vulnerable to the T315I gatekeeper mutation. Third-generation ponatinib and the newly approved allosteric inhibitor asciminib, which specifically targets the ABL myristoyl pocket, provide effective options for salvage-resistant disease, though they necessitate proactive cardiovascular and metabolic risk mitigation. Standardized molecular monitoring remains essential to distinguish true resistance from nonadherence and to guide mutation-directed sequencing.
Conclusion
Modern CML management has transitioned from uniform kinase inhibition toward highly individualized survivorship. Optimizing long-term quality of life relies on aligning tyrosine kinase inhibitor selection with patient-specific comorbidities, implementing response-adjusted dosing, and utilizing well-defined clinical parameters to safely evaluate candidates for treatment-free remission.
Zitieren
APA
Pinnelli, V. B. K., Thangachi, S. B., Anjanappa, J. C., Kandi, V., Murthuza, A. A., & Chenoly, S. K. (2026). Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives. Eurasian Journal of Medicine and Oncology, 10(5), 026270318. https://doi.org/10.36922/ejmo026270318
Vancouver
Pinnelli VBK, Thangachi SB, Anjanappa JC, Kandi V, Murthuza AA, Chenoly SK. Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives. Eurasian Journal of Medicine and Oncology. 2026;10(5):026270318. doi:10.36922/ejmo026270318
BibTeX
@article{Pinnelli2026,
author = {Pinnelli, Venkata Bharat Kumar and Thangachi, Surendra Babu and Anjanappa, Jayashankar Chinnappa and Kandi, Venkataramana and Murthuza, Aga Ammar and Chenoly, Shabina Komath},
title = {Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {10},
number = {5},
pages = {026270318},
doi = {10.36922/ejmo026270318}
}
EUVIMED